Fate Therapeutics Stock (NASDAQ:FATE)



Previous Close

$1.27

52W Range

$1.04 - $8.83

50D Avg

$1.63

200D Avg

$3.05

Market Cap

$161.73M

Avg Vol (3M)

$2.86M

Beta

2.02

Div Yield

-

FATE Company Profile


Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

181

IPO Date

Oct 01, 2013

Website

FATE Performance


Total Return %
1D
5D
1M
3M
6M
YTD
1Y
3Y
5Y
10Y
FATE
S&P 500
11.81%
19.33%
11.81%
-29.70%
-58.24%
-20.67%
-79.89%
-95.79%
-95.09%
-71.71%
-0.00%
1.75%
2.03%
4.09%
9.99%
4.29%
22.74%
39.50%
81.06%
190.18%

Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 23Dec 22Dec 20
Upfront Fee And Equity Premium$31.20M$23.10M$6.50M

Fiscal year ends in Dec 23 | Currency in USD

FATE Financial Summary


Dec 23Dec 22Dec 21
Revenue$63.53M$96.30M$55.85M
Operating Income$-177.61M$-308.39M$-216.99M
Net Income$-160.93M$-255.06M$-206.30M
EBITDA$-159.33M$-308.39M$-215.69M
Basic EPS$-1.64$-2.63$-2.18
Diluted EPS$-1.64$-2.63$-2.18

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q1 24May 09, 24 | 5:00 PM
Q4 23Feb 26, 24 | 5:00 PM
Q3 23Nov 08, 23 | 5:00 PM

Peer Comparison


TickerCompany
IPSCCentury Therapeutics, Inc.
RCUSArcus Biosciences, Inc.
EDITEditas Medicine, Inc.
RLAYRelay Therapeutics, Inc.
BEAMBeam Therapeutics Inc.
VERVVerve Therapeutics, Inc.
CRSPCRISPR Therapeutics AG
SANASana Biotechnology, Inc.
NTLAIntellia Therapeutics, Inc.
BPMCBlueprint Medicines Corporation
PRMEPrime Medicine, Inc.
ATRAAtara Biotherapeutics, Inc.
CRBUCaribou Biosciences, Inc.